查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1748864

氯沙坦市场－全球产业规模、份额、趋势、机会和预测，按来源、应用、地区和竞争细分，2020-2030 年

Losartan Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Source, By Application, By Region and Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

2024 年全球氯沙坦市场价值为 7.285 亿美元，预计到 2030 年将达到 8.9816 亿美元，复合年增长率为 3.75%。氯沙坦是一种血管张力素 II 受体阻断剂 (ARB)，广泛用于治疗高血压、心臟衰竭和糖尿病肾病变。其临床疗效、可负担性和安全性使其在全球各种医疗保健系统中广泛应用。肥胖、高血压和第 2 型糖尿病等生活型态相关疾病的负担日益加重，尤其是在老年人口中，大大增加了对氯沙坦等抗高血压药物的需求。此外，大众对慢性病预防意识的提高、仿製药行业的成长以及可及性治疗的推广，进一步推动了市场扩张。然而，与污染相关的产品召回以及激烈的仿製药竞争导致的持续价格压力等挑战削弱了一些製造商的盈利能力。儘管有这些限制，氯沙坦仍然是成熟市场和新兴市场心血管治疗的主要药物。

市场概览
预测期 2026-2030
2024年市场规模 7.285亿美元
2030年市场规模 8.9816亿美元
2025-2030 年复合年增长率 3.75%
成长最快的领域 合约製造组织
最大的市场 北美洲

关键市场驱动因素

医疗保健产业的成长

主要市场挑战

供应链中断

主要市场趋势

加强联合疗法研究

目录

第 1 章：产品概述

第二章：研究方法

第三章：执行摘要

第四章：COVID-19 对全球氯沙坦市场的影响

第五章：全球氯沙坦市场展望

  • 市场规模和预测
    • 按价值
  • 市场占有率和预测
    • 按来源（合约製造组织、内部）
    • 依用途（高血压、中风、糖尿病肾病变、其他）
    • 按地区
    • 按公司分类（2024）
  • 市场地图

第六章：北美氯沙坦市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 北美：国家分析
    • 美国
    • 墨西哥
    • 加拿大

第七章：欧洲氯沙坦市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 欧洲：国家分析
    • 法国
    • 德国
    • 英国
    • 义大利
    • 西班牙

第八章：亚太地区氯沙坦市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 亚太地区：国家分析
    • 中国
    • 印度
    • 韩国
    • 日本
    • 澳洲

第九章：南美洲氯沙坦市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 南美洲：国家分析
    • 巴西
    • 阿根廷
    • 哥伦比亚

第 10 章：中东和非洲氯沙坦市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • MEA：国家分析
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋

第 11 章：市场动态

  • 驱动程式
  • 挑战

第 12 章：市场趋势与发展

  • 合併与收购（如有）
  • 产品发布（如有）
  • 最新动态

第十三章：干扰：衝突、流行病与贸易壁垒

第 14 章：全球氯沙坦市场：SWOT 分析

第 15 章：波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的力量
  • 顾客的力量
  • 替代产品的威胁

第 16 章：竞争格局

  • Merck & Co. Inc.
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi SA
  • Novartis International AG
  • Dr. Reddy's Laboratories Ltd.
  • Sun Pharmaceuticals Industries Ltd.
  • Aurobindo Pharma Ltd.
  • Torrent Pharmaceutical Ltd.
  • Lupin Ltd.

第 17 章：策略建议

第18章调查会社について・免责事项

简介目录
Product Code: 7269

The Global Losartan Market was valued at USD 728.50 Million in 2024 and is projected to reach USD 898.16 Million by 2030, growing at a CAGR of 3.75%. Losartan, an angiotensin II receptor blocker (ARB), is extensively prescribed for managing hypertension, heart failure, and diabetic nephropathy. Its clinical efficacy, affordability, and safety profile have contributed to its broad utilization across diverse global healthcare systems. The growing burden of lifestyle-related illnesses such as obesity, hypertension, and type 2 diabetes-especially among aging populations-has significantly bolstered demand for antihypertensive medications like losartan. Additionally, increasing public awareness around chronic disease prevention, the growth of the generic pharmaceutical sector, and the promotion of accessible treatments are further propelling market expansion. However, challenges such as product recalls linked to contamination and sustained pricing pressures due to intense generic competition have tempered profitability for some manufacturers. Despite these constraints, losartan remains a mainstay in cardiovascular therapy across both mature and emerging markets.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 728.50 Million
Market Size 2030USD 898.16 Million
CAGR 2025-20303.75%
Fastest Growing SegmentContract Manufacturing Organizations
Largest MarketNorth America

Key Market Drivers

Growth in Healthcare Industry

The robust expansion of the global healthcare sector, with annual sales surpassing USD 4 trillion, continues to drive the growth of the losartan market. Key segments such as pharmaceuticals and biotechnology account for over USD 850 billion, while diagnostics and medical technology contribute more than USD 400 billion. As healthcare systems worldwide scale up to meet the rising prevalence of chronic conditions, there is heightened focus on early intervention and long-term management strategies for cardiovascular and renal diseases. This has elevated the demand for effective antihypertensive agents, with losartan positioned as a first-line option due to its efficacy in managing blood pressure and reducing the risk of stroke and kidney damage in diabetic patients. Increased healthcare spending, particularly in developing countries, along with broader access to generics, is further accelerating market growth.

Key Market Challenges

Disruption in Supply Chain

Supply chain disruptions pose a persistent challenge to the global losartan market, impacting the availability and timely distribution of both active pharmaceutical ingredients (APIs) and finished formulations. The production of losartan heavily depends on stable API sourcing, predominantly from manufacturing hubs in India and China. Any disruption caused by regulatory non-compliance, factory shutdowns, environmental restrictions, or geopolitical tensions can lead to delays and shortages. In addition, reliance on limited global suppliers creates bottlenecks, especially during periods of heightened demand. These interruptions not only affect drug availability but can also lead to price fluctuations, undermining supply chain resilience and complicating inventory management for manufacturers and healthcare providers alike.

Key Market Trends

Increasing Research into Combination Therapies

A growing trend shaping the losartan market is the increasing focus on fixed-dose combination therapies for the treatment of hypertension and related cardiovascular disorders. With the complexity of disease management rising, pharmaceutical companies are exploring synergistic formulations that combine losartan with complementary antihypertensive agents such as hydrochlorothiazide or amlodipine. These combination therapies aim to improve therapeutic outcomes, simplify dosing regimens, and boost patient adherence. Inspired by successful models in oncology and other chronic disease areas, this trend is supported by clinical data demonstrating enhanced efficacy and patient satisfaction. Fixed-dose combinations also offer pharmaceutical companies a pathway to differentiate their products in a competitive generic market, helping to extend product lifecycles and align with evolving clinical guidelines that prioritize combination treatment strategies.

Key Market Players

  • Merck & Co. Inc.
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi S.A.
  • Novartis International AG
  • Dr. Reddy's Laboratories Ltd.
  • Sun Pharmaceuticals Industries Ltd.
  • Aurobindo Pharma Ltd.
  • Torrent Pharmaceutical Ltd.
  • Lupin Ltd.

Report Scope

In this report, the Global Losartan Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Losartan Market, By Source:

  • Contract Manufacturing Organizations
  • In-House

Losartan Market, By Application:

  • Hypertension
  • Stroke
  • Diabetic Nephropathy
  • Others

Losartan Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Losartan Market.

Available Customizations

Global Losartan Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, and Trends

4. Impact of COVID-19 on Global Losartan Market

5. Global Losartan Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Source (Contract Manufacturing Organizations, In-House)
    • 5.2.2. By Application (Hypertension, Stroke, Diabetic Nephropathy, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2024)
  • 5.3. Market Map

6. North America Losartan Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Source
    • 6.2.2. By Application
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Losartan Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Source
        • 6.3.1.2.2. By Application
    • 6.3.2. Mexico Losartan Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Source
        • 6.3.2.2.2. By Application
    • 6.3.3. Canada Losartan Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Source
        • 6.3.3.2.2. By Application

7. Europe Losartan Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Source
    • 7.2.2. By Application
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Losartan Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Source
        • 7.3.1.2.2. By Application
    • 7.3.2. Germany Losartan Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Source
        • 7.3.2.2.2. By Application
    • 7.3.3. United Kingdom Losartan Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Source
        • 7.3.3.2.2. By Application
    • 7.3.4. Italy Losartan Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Source
        • 7.3.4.2.2. By Application
    • 7.3.5. Spain Losartan Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Source
        • 7.3.5.2.2. By Application

8. Asia Pacific Losartan Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Source
    • 8.2.2. By Application
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Losartan Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Source
        • 8.3.1.2.2. By Application
    • 8.3.2. India Losartan Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Source
        • 8.3.2.2.2. By Application
    • 8.3.3. South Korea Losartan Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Source
        • 8.3.3.2.2. By Application
    • 8.3.4. Japan Losartan Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Source
        • 8.3.4.2.2. By Application
    • 8.3.5. Australia Losartan Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Source
        • 8.3.5.2.2. By Application

9. South America Losartan Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Source
    • 9.2.2. By Application
    • 9.2.3. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Losartan Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Source
        • 9.3.1.2.2. By Application
    • 9.3.2. Argentina Losartan Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Source
        • 9.3.2.2.2. By Application
    • 9.3.3. Colombia Losartan Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Source
        • 9.3.3.2.2. By Application

10. Middle East and Africa Losartan Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Source
    • 10.2.2. By Application
    • 10.2.3. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Losartan Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Source
        • 10.3.1.2.2. By Application
    • 10.3.2. Saudi Arabia Losartan Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Source
        • 10.3.2.2.2. By Application
    • 10.3.3. UAE Losartan Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Source
        • 10.3.3.2.2. By Application

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Disruptions : Conflicts, Pandemics and Trade Barriers

14. Global Losartan Market: SWOT Analysis

15. Porters Five Forces Analysis

  • 15.1. Competition in the Industry
  • 15.2. Potential of New Entrants
  • 15.3. Power of Suppliers
  • 15.4. Power of Customers
  • 15.5. Threat of Substitute Products

16. Competitive Landscape

  • 16.1. Merck & Co. Inc.
    • 16.1.1. Business Overview
    • 16.1.2. Company Snapshot
    • 16.1.3. Products & Services
    • 16.1.4. Financials (As Reported)
    • 16.1.5. Recent Developments
    • 16.1.6. Key Personnel Details
    • 16.1.7. SWOT Analysis
  • 16.2. Pfizer Inc.
  • 16.3. Teva Pharmaceutical Industries Ltd.
  • 16.4. Sanofi S.A.
  • 16.5. Novartis International AG
  • 16.6. Dr. Reddy's Laboratories Ltd.
  • 16.7. Sun Pharmaceuticals Industries Ltd.
  • 16.8. Aurobindo Pharma Ltd.
  • 16.9. Torrent Pharmaceutical Ltd.
  • 16.10. Lupin Ltd.

17. Strategic Recommendations

18. About Us & Disclaimer